Azuma M - Search Results

1

Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer.

Seya T, Azuma M, Matsumoto M. Seya T, et al. Among authors: azuma m. Expert Opin Ther Targets. 2013 May;17(5):533-44. doi: 10.1517/14728222.2013.765407. Epub 2013 Feb 18. Expert Opin Ther Targets. 2013. PMID: 23414438 Review.

2

IPS-1 is essential for type III IFN production by hepatocytes and dendritic cells in response to hepatitis C virus infection.

Okamoto M, Oshiumi H, Azuma M, Kato N, Matsumoto M, Seya T. Okamoto M, et al. Among authors: azuma m. J Immunol. 2014 Mar 15;192(6):2770-7. doi: 10.4049/jimmunol.1301459. Epub 2014 Feb 14. J Immunol. 2014. PMID: 24532585

3

A MAVS/TICAM-1-independent interferon-inducing pathway contributes to regulation of hepatitis B virus replication in the mouse hydrodynamic injection model.

Leong CR, Oshiumi H, Okamoto M, Azuma M, Takaki H, Matsumoto M, Chayama K, Seya T. Leong CR, et al. Among authors: azuma m. J Innate Immun. 2015;7(1):47-58. doi: 10.1159/000365113. Epub 2014 Aug 8. J Innate Immun. 2015. PMID: 25115498 Free PMC article.

4

Pam2 lipopeptides systemically increase myeloid-derived suppressor cells through TLR2 signaling.

Maruyama A, Shime H, Takeda Y, Azuma M, Matsumoto M, Seya T. Maruyama A, et al. Among authors: azuma m. Biochem Biophys Res Commun. 2015 Feb 13;457(3):445-50. doi: 10.1016/j.bbrc.2015.01.011. Epub 2015 Jan 13. Biochem Biophys Res Commun. 2015. PMID: 25596131

5

Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo.

Matsumoto M, Tatematsu M, Nishikawa F, Azuma M, Ishii N, Morii-Sakai A, Shime H, Seya T. Matsumoto M, et al. Among authors: azuma m. Nat Commun. 2015 Feb 18;6:6280. doi: 10.1038/ncomms7280. Nat Commun. 2015. PMID: 25692975 Free article.

6

Double-stranded RNA analog and type I interferon regulate expression of Trem paired receptors in murine myeloid cells.

Kasamatsu J, Deng M, Azuma M, Funami K, Shime H, Oshiumi H, Matsumoto M, Kasahara M, Seya T. Kasamatsu J, et al. Among authors: azuma m. BMC Immunol. 2016 May 3;17(1):9. doi: 10.1186/s12865-016-0147-y. BMC Immunol. 2016. PMID: 27141827 Free PMC article.

7

Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy.

Seya T, Takeda Y, Takashima K, Yoshida S, Azuma M, Matsumoto M. Seya T, et al. Among authors: azuma m. Proc Jpn Acad Ser B Phys Biol Sci. 2018;94(3):153-160. doi: 10.2183/pjab.94.011. Proc Jpn Acad Ser B Phys Biol Sci. 2018. PMID: 29526974 Free PMC article. Review.

8

Inhibition of lipid A-mediated type I interferon induction by bactericidal/permeability-increasing protein (BPI).

Azuma M, Matsuo A, Fujimoto Y, Fukase K, Hazeki K, Hazeki O, Matsumoto M, Seya T. Azuma M, et al. Biochem Biophys Res Commun. 2007 Mar 9;354(2):574-8. doi: 10.1016/j.bbrc.2007.01.019. Epub 2007 Jan 10. Biochem Biophys Res Commun. 2007. PMID: 17239348

9

Soluble G protein of respiratory syncytial virus inhibits Toll-like receptor 3/4-mediated IFN-beta induction.

Shingai M, Azuma M, Ebihara T, Sasai M, Funami K, Ayata M, Ogura H, Tsutsumi H, Matsumoto M, Seya T. Shingai M, et al. Among authors: azuma m. Int Immunol. 2008 Sep;20(9):1169-80. doi: 10.1093/intimm/dxn074. Epub 2008 Jul 8. Int Immunol. 2008. PMID: 18611945 Free article.

10

The peptide sequence of diacyl lipopeptides determines dendritic cell TLR2-mediated NK activation.

Azuma M, Sawahata R, Akao Y, Ebihara T, Yamazaki S, Matsumoto M, Hashimoto M, Fukase K, Fujimoto Y, Seya T. Azuma M, et al. PLoS One. 2010 Sep 2;5(9):e12550. doi: 10.1371/journal.pone.0012550. PLoS One. 2010. PMID: 20824059 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,398 results

Search Page

Filters